# Phase 2 lymphoma trials recruiting: 392 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 392 trials in phase 2 for lymphoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 lymphoma trials: 392 rows for $19.60, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lymphoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 392
- Recruiting or not yet: 392
- Read on: November 19, 2026

## Trials

The 25 newest of 392, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945353 | Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma | Fudan University | Phase 2 | Not yet recruiting | MALT Lymphoma | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945353) |
| November 18, 2026 | NCT07944651 | Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07944651) |
| November 16, 2026 | NCT07939685 | Entinostat + R-CHOP in Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL: Phase II Trial | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939685) |
| November 16, 2026 | NCT07938619 | Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07938619) |
| November 6, 2026 | NCT07921615 | QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Plasmablastic Lymphoma | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921615) |
| November 5, 2026 | NCT07920393 | Allogeneic Cell Therapy in Refractory T-Cell Lymphoma | University Medical Center Goettingen | Phase 2 | Not yet recruiting | Lymphoma, T Cell, Peripheral | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920393) |
| November 5, 2026 | NCT07917832 | Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Multi Center, Phase 2, Golcadomide, Glofitamab, Polauzumab, Vedotin, G2p, B Cell Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917832) |
| November 4, 2026 | NCT07917624 | Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917624) |
| November 2, 2026 | NCT07910435 | Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial | University of Washington | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910435) |
| October 26, 2026 | NCT07895017 | Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias | University of Virginia | Phase 2 | Not yet recruiting | Thrombocytopenia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895017) |
| October 23, 2026 | NCT07893197 | Ceritinib Treatment for Recurrent Meningiomas | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Recurrent Meningioma, Grade I and Grade II | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893197) |
| October 23, 2026 | NCT07892027 | Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma... | University of Michigan Rogel Cancer Center | Phase 2 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma... | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892027) |
| October 22, 2026 | NCT07888647 | IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas | German Cancer Research Center | Phase 2 | Not yet recruiting | Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888647) |
| October 20, 2026 | NCT07883135 | Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas | National Research Center for Hematology, Russia | Phase 2 | Recruiting | Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Relapsed or Refractory B-cell Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883135) |
| October 15, 2026 | NCT07875413 | Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875413) |
| October 2, 2026 | NCT07855016 | A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma | TransThera Sciences (Nanjing), Inc. | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma (MCL) | 188 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855016) |
| October 2, 2026 | NCT07854639 | A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma | Peking University First Hospital | Phase 2 | Not yet recruiting | Cutaneous T-Cell Lymphoma/Mycosis Fungoides/Sézary Syndrome | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854639) |
| September 15, 2026 | NCT07820033 | Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Randomized Controlled Trial | University Health Network, Toronto | Phase 2 | Not yet recruiting | Advanced Cancer, Stage IV Solid Tumor Cancer, Stage IV Sarcoma of Bone, Stage IV Lymphoma, Stage IV Melanoma, Endocrine... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820033) |
| September 14, 2026 | NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819396) |
| September 10, 2026 | NCT07814001 | Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy | The Lymphoma Academic Research Organisation | Phase 2 | Not yet recruiting | Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814001) |
| September 2, 2026 | NCT07799220 | A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma | Memorial Sloan Kettering Cancer Center | Phase 2 | Not yet recruiting | Mantle Cell Lymphoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07799220) |
| August 28, 2026 | NCT07791615 | A Phase II Study of Stapokibart Combined With Immune Checkpoint Inhibitors in Relapsed/Refractory Lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Lymphoma, NK T-Cell Lymphoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07791615) |
| August 25, 2026 | NCT07783594 | Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Randomized, Phase 2, Epcoritamab, Watch & Wait, Untreated, Tumor Burden, Follicular Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783594) |
| August 24, 2026 | NCT07781449 | Topical JAK-Inhibition of Early-Stage CTCL | Aarhus University Hospital | Phase 2 | Not yet recruiting | Mycosis Fungoides, Cutaneous T-cell Lymphoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781449) |
| August 21, 2026 | NCT07779018 | CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07779018) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Ruijin Hospital | 21 |
| M.D. Anderson Cancer Center | 17 |
| Institute of Hematology & Blood Diseases Hospital, China | 14 |
| Sun Yat-sen University | 13 |
| City of Hope Medical Center | 12 |
| National Cancer Institute (NCI) | 11 |
| Memorial Sloan Kettering Cancer Center | 9 |
| The First Affiliated Hospital with Nanjing Medical University | 9 |
| The First Affiliated Hospital of Soochow University | 8 |
| Fudan University | 7 |
| University of Washington | 6 |
| The First Affiliated Hospital of Xiamen University | 6 |
| H. Lee Moffitt Cancer Center and Research Institute | 5 |
| Tianjin Medical University Cancer Institute and Hospital | 5 |
| Masonic Cancer Center, University of Minnesota | 4 |
| Fondazione Italiana Linfomi - ETS | 4 |
| [Miltenyi Biomedicine GmbH](https://specstream.ai/data/clinical-trials/company/miltenyi-biomedicine-gmbh) | 4 |
| Fred Hutchinson Cancer Center | 4 |
| First Affiliated Hospital of Zhejiang University | 4 |
| SWOG Cancer Research Network | 4 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 4 |
| Beijing Tongren Hospital | 4 |
| Mayo Clinic | 3 |
| Canadian Cancer Trials Group | 3 |
| Peking Union Medical College Hospital | 3 |

## By country

| Country | Trials |
| --- | --- |
| United States | 160 |
| China | 133 |
| Canada | 14 |
| France | 14 |
| Italy | 14 |
| Germany | 13 |
| Australia | 12 |
| South Korea | 11 |
| Spain | 10 |
| United Kingdom | 9 |
| Poland | 6 |
| Puerto Rico | 6 |
| Taiwan | 4 |
| Belgium | 4 |
| Sweden | 3 |
| Czechia | 3 |
| Switzerland | 3 |
| Brazil | 3 |
| Denmark | 3 |
| Hungary | 3 |
| Israel | 3 |
| Singapore | 2 |
| Finland | 2 |
| Norway | 2 |
| Austria | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Armenian restaurants in the United States](https://specstream.ai/data/businesses/armenian-restaurants/united-states)
- [Traffic ticketing law firms in the United States](https://specstream.ai/data/businesses/traffic-ticketing-law-firms/united-states)
- [Resorts in the United States](https://specstream.ai/data/businesses/resorts/united-states)
- [Orthopedics practices in the United States](https://specstream.ai/data/businesses/orthopedics-practices/united-states)
- [Jewelry and watches manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-and-watches-manufacturers/united-states)
- [Furniture rental companies in the United States](https://specstream.ai/data/businesses/furniture-rental-companies/united-states)
